Related Experiment Video
Updated: Aug 23, 2026

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
Antibody therapy for non-Hodgkin's lymphoma
1Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN 55905, USA. ansell.stephen@mayo.edu
Abstract:
Significant advances in the therapy of non-Hodgkin's lymphoma have been made with the introduction of monoclonal antibodies. The anti-CD20 antibody rituximab has become standard as monotherapy in patients with indolent lymphoma, and in combination with chemotherapy in patients with aggressive lymphoma. A number of new monoclonal antibodies targeting different molecules on lymphoma cells are now in clinical development and show promise both as single agents and in combination therapy. Furthermore, anti-CD20 monoclonal antibodies have been radioconjugated to increase their efficacy. Future studies will therefore be needed to explore the efficacy of combinations of these agents and to develop a rational strategy for their use.
More Related Videos
Related Concept Videos
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

